Drug Trial Radar · NCT00249808
A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies
Last checked: Nov 19, 2026Latest source record: Mar 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,266
Actual
Start
Dec 13, 2004
Primary completion
Jan 25, 2007
Study completion Jan 25, 2007
Sponsor
- Lead sponsor
- Merck KGaA, Darmstadt, GermanyIndustry
- Sponsor type
- Industry
- First posted
- Nov 7, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase IIIb/IV, open label, multicentre study of efalizumab (anti cluster of differentiation \[CD\] 11a recombinant human monoclonal antibody) in participants with moderate to severe plaque psoriasis who have failed to respond to, have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate, and psoralen and ultraviolet A phototherapy (PUVA).
Conditions
- Psoriasis
Interventions
Efalizumab - anti-CD11a recombinant human monoclonal antibodyDrug
Participants will receive efalizumab 1.0 milligram per kilogram (mg/kg) (with an initial conditioning dose of 0.7 mg/kg) once weekly by subcutaneous injection for 12 weeks (first treatment \[FT\]). Depending on the response at Week 12, participants could receive additional 8 to 12 weekly injections of efalizumab 1.0 mg/kg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Physician's Global Assessment (PGA) Ratings of Good or Better (FT)Time frame: Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical Information
Feltham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.